EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC.
EGFR mutation testing in non-small cell lung cancer (NSCLC) is a novel and important molecular pathological diagnostic assay that is predictive of response to anti-epidermal growth factor receptor (EGFR) therapy. A comprehensive compilation of a large number of EGFR mutation analyses of the German Panel for Mutation Analyses in NSCLC demonstrates (a) a higher than previously reported mutation frequency outside the conventionally tested exons 19 and 21 and (b) an overall superiority of sequencing based assays over mutation-specific PCR. The implications for future diagnostic EGFR mutation testing are discussed.
Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 220, 69120, Heidelberg, Germany.
Roland
R
Penzel
Christine
C
Sers
Yuan
Y
Chen
Ulrich
U
Lehmann-Mühlenhoff
Sabine
S
Merkelbach-Bruse
Andreas
A
Jung
Thomas
T
Kirchner
Reinhard
R
Büttner
Hans H
HH
Kreipe
Iver
I
Petersen
Manfred
M
Dietel
Peter
P
Schirmacher
D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000235:genetics*; D055088:Early Detection of Cancer / Q000379:methods*; D066246:ErbB Receptors / Q000235:genetics*; D005091:Exons / Q000235:genetics; D005820:Genetic Testing / Q000379:methods; D005858:Germany; D006287:Health Planning Guidelines; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D016037:Single-Blind Method
D066246:ErbB Receptors